The ATNM chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ATNM chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The ATNM stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View ATNM Detailed Price Forecast - CNN Money||View ATNM Detailed Summary - Google Finance|
|View ATNM Detailed Summary - Yahoo! Finance||View ATNM Stock Research & Analysis - Zacks.com|
|View ATNM Trends & Analysis - Trade-Ideas||View ATNM Major Holders - Barrons|
|View ATNM Call Transcripts - NASDAQ||View ATNM Breaking News & Analysis - Seeking Alpha|
|View ATNM Annual Report - CompanySpotlight.com||View ATNM OTC Short Report - OTCShortReport.com|
|View ATNM Fundamentals - TradeKing||View ATNM SEC Filings - Bar Chart|
|View Historical Prices for ATNM - The WSJ||View Performance/Total Return for ATNM - Morningstar|
|View the Analyst Estimates for ATNM - MarketWatch||View the Earnings History for ATNM - CNBC|
|View the ATNM Earnings - StockMarketWatch||View ATNM Buy or Sell Recommendations - MacroAxis|
|View the ATNM Bullish Patterns - American Bulls||View ATNM Short Pain Metrics - ShortPainBot.com|
|View ATNM Stock Mentions - StockTwits||View ATNM Stock Mentions - PennyStockTweets|
|View ATNM Stock Mentions - Twitter||View ATNM Investment Forum News - Investor Hub|
|View ATNM Stock Mentions - Yahoo! Message Board||View ATNM Stock Mentions - Seeking Alpha|
|View Insider Transactions for ATNM - SECform4.com||View Insider Transactions for ATNM - Insider Cow|
|View ATNM Major Holdings Summary - CNBC||View Insider Disclosure for ATNM - OTC Markets|
|View Insider Transactions for ATNM - Yahoo! Finance||View Institutional Holdings for ATNM - NASDAQ|
|View ATNM Stock Insight & Charts - FinViz.com||View ATNM Investment Charts - StockCharts.com|
|View ATNM Stock Overview & Charts - BarChart||View ATNM User Generated Charts - Trading View|
NEW YORK, July 17, 2018-- Actinium Pharmaceuticals, Inc., today announced that it has appointed the members of its Nuclear Medicine Clinical Advisory Board. The following nuclear medicine physicians and ...
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN:ATNM) ("Actinium" or "the Company"), provided a reminder that it will host a webcast on July 10, 2018 at 8:00 AM ET. The webcast will discuss the Company’s previously announced Actimab-A MRD clinical trial for patients with AML who are in remission but have detectable minimal residual disease (MRD).
Breakfast Technical Briefing on Amarin and Three Other Additional Biotech Stocks
Posted on Monday July 02, 2018
On Friday, June 29, 2018, US markets saw broad based gains with six out of nine sectors finishing the trading sessions in green. All you have to do is sign up today for this free limited time offer by clicking the link below.
Actinium Announces New Clinical Trial to Study Effect of Actimab-A on Minimal Residual Disease in Postremission AML Patients
Posted on Thursday June 28, 2018
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN:ATNM) ("Actinium" or "the Company"), today announced that Dr. Joseph Jurcic, Director of the Hematologic Malignancies Section and Professor of Medicine at Columbia University Medical Center, has initiated Actimab-A MRD, a new clinical trial for patients with AML who are in remission but have detectable minimal residual disease (MRD). The trial will study the safety/tolerability of Actimab-A in the postremission consolidation setting and include dose finding analyses. The trial will also study the impact of Actimab-A on minimal residual disease (MRD) as well as progression-free (PFS) and overall survival (OS) rates. The investigational new drug (IND) application for this trial has been cleared by the FDA.